GENESEEQPRIME™
A comprehensive genomic profiling panel across all solid tumors
GeneseeqPrime™ analyzes 400+ cancer-related genes by next-generation sequencing. It reveals clinically actionable information for therapy selection by providing valuable insight into key oncogenic genes and drug resistance mechanisms.
WHO IS IT FOR
Patients with solid tumors seeking precision medicine
SAMPLE TYPES
Tumor tissue (FFPE block/slides, or frozen tissue)
Fine needle biopsy
Liquid biopsy (plasma and others)
All-in-one test for 400+ cancer-related genes
Identifies numerous mutation types: single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), gene fusions and large genomic rearrangements (LGR)
Assesses key biomarkers: tumor mutation burden (TMB), microsatellite instability (MSI), DNA mismatch repair (MMR) genes, homologous recombination repair (HRR) genes
GeneseeqPrime™ Report
Provides information on clinically actionable genomic alterations and their associated targeted therapy, both approved drugs and those in clinical trials
Evaluates TMB and MSI to better inform immunotherapy decisions
Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
Reveals potential resistance mechanisms to current therapies and options for alternative treatments
Assesses genetic predisposition to certain cancer types for early intervention
LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.
Learn more about our products and services or contact us today to discuss how we can partner together.
